Induction of the mesenchymal to epithelial transition by demethylation- activated microRNA-200c is involved in the anti-migration/invasion effects of arsenic trioxide on human breast cancer cells

Molecular Carcinogenesis

Volumn 54, Issue 9, 2015, Pages 859-869

  Si, Lu ^a   Jiang, Fei ^a   Li, Yuan ^a   Ye, Xianqing ^a   Mu, Juan ^a   Wang, Xingxing ^a   Ning, Shilong ^a   Hu, Chunyan ^a   Li, Zhong ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Arsenic trioxide; Breast cancer; Mesenchymal to epithelial transition; MicroRNA 200c; Migration invasion

Indexed keywords

ANTIMETASTATIC AGENT; ARSENIC TRIOXIDE; MESSENGER RNA; MICRORNA 141; MICRORNA 200C; NERVE CELL ADHESION MOLECULE; UVOMORULIN; VIMENTIN; ANTINEOPLASTIC AGENT; MICRORNA; MIRN200 MICRORNA, HUMAN; ORGANOARSENIC DERIVATIVE; OXIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BREAST CANCER CELL LINE; CELL MIGRATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DEMETHYLATION; DNA METHYLATION; DRUG TRANSFORMATION; EPITHELIAL MESENCHYMAL TRANSITION; GENE OVEREXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; METASTASIS INHIBITION; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR INVASION; UPREGULATION; WESTERN BLOTTING; BREAST; BREAST NEOPLASMS; CELL MOTION; DRUG EFFECTS; FEMALE; GENE EXPRESSION REGULATION; GENETICS; METHYLATION; NEOPLASM INVASIVENESS; PATHOLOGY; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; ARSENICALS; BREAST; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL MOVEMENT; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; METHYLATION; MICRORNAS; NEOPLASM INVASIVENESS; OXIDES; UP-REGULATION;

EID: 84938980295     PISSN: 08991987     EISSN: 10982744     Source Type: Journal    
DOI: 10.1002/mc.22157     Document Type: Article

References (40)

1. Ahmad A, Sarkar SH, Bitar B, et al. Garcinol regulates EMT and Wnt signaling pathways in vitro and in vivo, leading to anticancer activity against breast cancer cells. Mol Cancer Ther 2012; 11:2193-2201.
2. Redig AJ, McAllister SS. Breast cancer as a systemic disease: A view of metastasis. J Intern Med 2013; 274:113-126.
3. Du J, Zhou N, Liu H, et al. Arsenic induces functional re-expression of estrogen receptor alpha by demethylation of DNA in estrogen receptor-negative human breast cancer. PLoS ONE 2012; 7:e35957.
4. Xia J, Li Y, Yang Q, et al. Arsenic trioxide inhibits cell growth and induces apoptosis through inactivation of notch signaling pathway in breast cancer. Int J Mol Sci 2012; 13:9627-9641.
5. Thomas DJ, Nava GM, Cai SY, Boyer JL, Hernandez-Zavala A, Gaskins HR. Arsenic (+ 3 oxidation state) methyltransferase and the methylation of arsenicals in the invertebrate chordate Ciona intestinalis. Toxicol Sci 2010; 113:70-76.
6. Li X, Roslan S, Johnstone CN, et al. MiR-200 can repress breast cancer metastasis through ZEB1-independent but moesin-dependent pathways. Oncogene 2013 [Epub ahead of print].
7. Radisky DC. miR-200c at the nexus of epithelial-mesenchymal transition, resistance to apoptosis, and the breast cancer stem cell phenotype. Breast Cancer Res 2011; 13:110.
8. Huang Q, Gumireddy K, Schrier M, et al. The microRNAs miR-373 and miR-520c promote tumour invasion and metastasis. Nat Cell Biol 2008; 10:202-210.
9. Li T, Leong MH, Harms B, Kennedy G, Chen L. MicroRNA-21 as a potential colon and rectal cancer biomarker. World J Gastroenterol 2013; 19:5615-5621.
10. Hur K, Toiyama Y, Takahashi M, et al. MicroRNA-200c modulates epithelial-to-mesenchymal transition (EMT) in human colorectal cancer metastasis. Gut 2013; 62:1315-1326.
11. Liang YJ, Wang QY, Zhou CX, et al. MiR-124 targets Slug to regulate epithelial-mesenchymal transition and metastasis of breast cancer. Carcinogenesis 2013; 34:713-722.
12. Oh JS, Kim JJ, Byun JY, Kim IA. Lin28-let7 modulates radiosensitivity of human cancer cells with activation of K-Ras. Int J Radiat Oncol Biol Phys 2010; 76:5-8.
13. Tellez CS, Juri DE, Do K, et al. EMT and stem cell-like properties associated with miR-205 and miR-200 epigenetic silencing are early manifestations during carcinogen-induced transformation of human lung epithelial cells. Cancer Res 2011; 71:3087-3097.
14. Lombaerts M, van Wezel T, Philippo K, et al. E-cadherin transcriptional downregulation by promoter methylation but not mutation is related to epithelial-to-mesenchymal transition in breast cancer cell lines. Br J Cancer 2006; 94:661-671.
15. Micalizzi DS, Farabaugh SM, Ford HL. Epithelial-mesenchymal transition in cancer: Parallels between normal development and tumor progression. J Mammary Gland Biol Neoplasia 2010; 15:117-134.
16. Vrba L, Jensen TJ, Garbe JC, et al. Role for DNA methylation in the regulation of miR-200c and miR-141 expression in normal and cancer cells. PLoS ONE 2010; 5:e8697.
17. Miles DW, de Haas SL, Dirix LY, et al. Biomarker results from the AVADO phase 3 trial of first-line bevacizumab plus docetaxel for HER2-negative metastatic breast cancer. Br J Cancer 2013; 108:1052-1060.
18. Franco-Chuaire ML, Magda Carolina SC, Chuaire-Noack L. Epithelial-mesenchymal transition (EMT): Principles and clinical impact in cancer therapy. Invest Clin 2013; 54:186-205.
19. Chen TC, Hsu YL, Tsai YC, et al. Gemifloxacin inhibits migration and invasion and induces mesenchymal-epithelial transition in human breast adenocarcinoma cells. J Mol Med 2014; 92:53-64.
20. Romero-Perez L, Lopez-Garcia MA, Diaz-Martin J, et al. ZEB1 overexpression associated with E-cadherin and microRNA-200 downregulation is characteristic of undifferentiated endometrial carcinoma. Mod Pathol 2013; 26:1514-1524.
21. Cui X, Wakai T, Shirai Y, Yokoyama N, Hatakeyama K, Hirano S. Arsenic trioxide inhibits DNA methyltransferase and restores methylation-silenced genes in human liver cancer cells. Human Pathol 2006; 37:298-311.
22. Ghaffari SH, Bashash D, Dizaji MZ, Ghavamzadeh A, Alimoghaddam K. Alteration in miRNA gene expression pattern in acute promyelocytic leukemia cell induced by arsenic trioxide: A possible mechanism to explain arsenic multi-target action. Tumour Biol 2012; 33:157-172.
23. Lallemand-Breitenbach V, Guillemin MC, Janin A, et al. 1999; Retinoic acid and arsenic synergize to eradicate leukemic cells in a mouse model of acute promyelocytic leukemia. J Exp Med 189:1043-1052.
24. 3) inhibits peritoneal invasion of ovarian carcinoma cells in vitro and in vivo. Gynecol Oncol 2006; 103:199-206.
25. 3) in the orthotopic metastasis model of androgen-independent prostate cancer. Cancer Res 2001; 61:5432-5440.
26. Soucy NV, Ihnat MA, Kamat CD, et al. Arsenic stimulates angiogenesis and tumorigenesis in vivo. Toxic Sci 2003; 76:271-279.
27. Liu W, Gong Y, Li H, et al. Arsenic trioxide-induced growth arrest of breast cancer MCF-7 cells involving FOXO3a and IkappaB kinase beta expression and localization. Cancer Biother Radiopharm 2012; 27:504-512.
28. Lim YY, Wright JA, Attema JL, et al. Epigenetic modulation of the miR-200 family is associated with transition to a breast cancer stem-cell-like state. J Cell Sci 2013; 126:2256-2266.
29. Castilla MA, Diaz-Martin J, Sarrio D, et al. MicroRNA-200 family modulation in distinct breast cancer phenotypes. PLoS ONE 2012; 7:e47709.
30. Rajabi H, Alam M, Takahashi H, et al. MUC1-C oncoprotein activates the ZEB1/miR-200c regulatory loop and epithelial-mesenchymal transition. Oncogene 2014; 33:1680-1689.
31. Engelsvold DH, Utheim TP, Olstad OK, et al. miRNA and mRNA expression profiling identifies members of the miR-200 family as potential regulators of epithelial-mesenchymal transition in pterygium. Exptl Eye Res 2013; 115C:189-198.
32. Cui X, Wakai T, Shirai Y, et al. Arsenic trioxide inhibits DNA methyltransferase and restores methylation-silenced genes in human liver cancer cells. Hum Pathol 2006; 37:298-311.
33. Du C, Yang P, Zhang G, et al. Effect of arsenic trioxide on EBV LMP1 mediated E-cadherin silencing in nasopharyngeal carcinoma. Head Neck Oncol 2012; 4:55.
34. 3) reduces the invasive and metastatic properties of cervical cancer cells in vitro and in vivo. Gynecol Oncol 2007; 106:400-406.
35. Wik E, Raeder MB, Krakstad C, et al. Lack of estrogen receptor-a is associated with epithelial-mesenchymal transition and PI3K alterations in endometrial carcinoma. Clin Cancer Res 2013; 19:1094-1105.
36. Ye Y, Xiao Y, Wang W, et al. ERα suppresses slug expression directly by transcriptional repression. Biochem J 2008; 416:179-187.
37. Chik F, Machnes Z, Szyf M. Synergistic anti breast cancer effect of a combined treatment with the methyl donor S-adenosyl methionine (SAM) with the DNA methylation inhibitor 5-aza-2'-deoxycytidine. Carcinogenesis 2014; 35:138-144.
38. Arabsolghar R, Azimi T, Rasti M. Mutant p53 binds to estrogen receptor negative promoter via DNMT1 and HDAC1 in MDA-MB-468 breast cancer cells. Mol Biol Rep 2013; 40:2617-2625.
39. Kullmann K, Deryal M, Ong MF, Schmidt W, Mahlknecht U. DNMT1 genetic polymorphisms affect breast cancer risk in the central European Caucasian population. Clin Epigen 2013; 5:7.
40. Hayden A, Johnson PW, Packham G, Crabb SJ. S-Adenosylhomocysteine hydrolase inhibition by 3-deazaneplanocin A analogues induces anti-cancer effects in breast cancer cell lines and synergy with both histone deacetylase and HER2 inhibition. Breast Cancer Res Treat 2011; 127:109-119.